News & Events
Crinetics Pharmaceuticals Announces Oversubscribed $350 Million Private Placement
Crinetics announces that it has agreed to sell 8,333,334 shares of its common stock at a price of $42.00 per...
READ MORECrinetics Pharmaceuticals To Report Fourth Quarter And Full Year 2023 Financial Results On February 28, 2024
Event Date: Crinetics will host a conference call and webcast on February 28th at 4:30 p.m. ET to discuss fourth quarter and full year 2023 financial results and provide a business update.
READ MORECrinetics Announces February 2024 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Crinetics granted non-qualified stock option awards to purchase an aggregate of 73,000 shares of its common stock to nine new...
READ MORECrinetics Announces January 2024 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Crinetics granted non-qualified stock option awards to purchase an aggregate of 112,500 shares of its common stock to eight new...
READ MORECrinetics Pharmaceuticals to Participate in the 42nd Annual J.P. Morgan Healthcare Conference
Crinetics Pharmaceuticals to Participate in the 42nd Annual J.P. Morgan Healthcare Conference
READ MORECrinetics Positive Initial Findings from Ongoing Open-Label Phase 2 Study of Paltusotine for the Treatment of Carcinoid Syndrome
Event Date: December 18, 2023
READ MORECrinetics Announces Positive Initial Findings from Ongoing Open-Label Phase 2 Study of Paltusotine for the Treatment of Carcinoid Syndrome
Crinetics announces positive initial findings from its ongoing open-label Phase 2 carcinoid syndrome study of paltusotine, an oral, once-daily investigational...
READ MORECrinetics Announces December 2023 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Crinetics granted non-qualified stock option awards to purchase an aggregate of 94,000 shares of its common stock to six new...
READ MORETransforming Endocrine Disease Treatment
Be the first to know about the advances we're making in endocrine-rooted care.